The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Antibodies to watch in 2020
Open accessAbstract
This 2020 installment of the annual ‘Antibodies to Watch’ series documents the antibody therapeutics approved in 2019 and in regulatory review in the United States or European Union, as well as those in late-stage clinical studies, as of November 2019*. At this time, a total of 5 novel antibody therapeutics (romosozumab, risankizumab, polatuzumab vedotin, brolucizumab, and crizanlizumab) had been granted a first approval in either the US or EU, and marketing applications for 13 novel antibody therapeutics (eptinezumab, teprotumumab, enfortumab vedotin, isatuximab, [fam-]trastuzumab deruxtecan, inebilizumab, leronlimab, sacituzumab govitecan, satralizumab, narsoplimab, tafasitamab, REGNEB3 and naxituximab) were undergoing review in these regions, which represent the major markets for antibody therapeutics. Also as of November 2019, 79 novel antibodies were undergoing evaluation in late-stage clinical studies. Of the 79 antibodies, 39 were undergoing evaluation in late-stage studies for non-cancer indications, with 2 of these (ublituximab, pamrevlumab) also in late-stage studies for cancer indications. Companies developing 7 (tanezumab, aducanumab, evinacumab, etrolizumab, sutimlimab, anifrolumab, and teplizumab) of the 39 drugs have indicated that they may submit a marketing application in either the US or EU in 2020. Of the 79 antibodies in late-stage studies, 40 were undergoing evaluation as treatments for cancer, and potentially 9 of these (belantamab mafodotin, oportuzumab monatox, margetuximab, dostarlimab, spartalizumab, 131I-omburtamab, loncastuximab tesirine, balstilimab, and zalifrelimab) may enter regulatory review in late 2019 or in 2020. Overall, the biopharmaceutical industry’s clinical pipeline of antibody therapeutics is robust, and should provide a continuous supply of innovative products for patients in the future. *Note on key updates through December 18, 2019: 1) the US Food and Drug Administration granted accelerated approval to enfortumab vedotin-ejfv (Padcev) on December 18, 2019, bringing the total number of novel antibody therapeutics granted a first approval in either the US or EU during 2019 to 6; 2) the European Commission approved romosozumab on December 9, 2019; 3) the European Medicines Agency issued a positive opinion for brolucizumab; 4) Sesen Bio initiated a rolling biologics license application (BLA) on December 6, 2019; 5) GlaxoSmithKline submitted a BLA for belantamab mafodotin; and 6) the status of the Phase 3 study (NCT04128696) of GSK3359609, a humanized IgG4 anti-ICOS antibody, in patients with head and neck squamous cell carcinoma was updated to recruiting from not yet recruiting.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Randomized, Controlled Trial of Ebola Virus Disease Therapeutics
Mulangu, S., Dodd, L. E., Davey, R. T., Tshiani Mbaya, O., Proschan, M., Mukadi, D., Lusakibanza Manzo, M., Nzolo, D., Tshomba Oloma, A., Ibanda, A., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1910993 · Cited by 1,605
An anti-CD3 antibody, teplizumab, in relatives at risk for type 1 diabetes
Herold, K. C., Bundy, B. N., Long, S. A., Bluestone, J. A., DiMeglio, L. A., Dufort, M. J., Gitelman, S. E., Gottlieb, P. A., Krischer, J. P., Linsley, P. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1902226 · Cited by 1,189
Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., Gomes, A. V., Warburton, J., Weichselberger, A., & Holz, F. G. (2020) · Ophthalmology · doi:10.1016/j.ophtha.2019.04.017 · Cited by 931
Cree, B. A. C., Bennett, J. L., Kim, H. J., Weinshenker, B. G., Pittock, S. J., Wingerchuk, D. M., Fujihara, K., Paul, F., Cutter, G. R., Marignier, R., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)31817-3 · Cited by 756 · cited 1×
“Inebilizumab demonstrated a favorable safety and tolerability profile, with an adverse event rate similar to placebo.(47)”
BackgroundTeprotumumab for Thyroid-Associated Ophthalmopathy
Smith, T. J., Kahaly, G. J., Ezra, D. G., Fleming, J. C., Dailey, R. A., Tang, R. A., Harris, G. J., Antonelli, A., Salvi, M., Goldberg, R. A., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1614949 · Cited by 756
Gordon, K. B., Strober, B., Lebwohl, M., Augustin, M., Blauvelt, A., Poulin, Y., Papp, K. A., Sofen, H., Puig, L., Foley, P., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31713-6 · Cited by 678
Trial of Satralizumab in Neuromyelitis Optica Spectrum Disorder
Yamamura, T., Kleiter, I., Fujihara, K., Palace, J., Greenberg, B., Zakrzewska-Pniewska, B., Patti, F., Tsai, C.-P., Saiz, A., Yamazaki, H., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1901747 · Cited by 664
Kaplon, H., & Reichert, J. M. (2019) · mAbs · doi:10.1080/19420862.2018.1556465 · Cited by 434
Self-citationStructural and kinetic basis for the selectivity of aducanumab for aggregated forms of amyloid-β
Arndt, J. W., Qian, F., Smith, B. A., Quan, C., Kilambi, K. P., Bush, M. W., Walz, T., Pepinsky, R. B., Bussière, T., Hamann, S., et al. (2018) · Scientific Reports · doi:10.1038/s41598-018-24501-0 · Cited by 365
Morgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1133 · Cited by 326
Reich, K., Gooderham, M., Thaçi, D., Crowley, J. J., Ryan, C., Krueger, J. G., Tsai, T.-F., Flack, M., Gu, Y., Williams, D. A., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)30952-3 · Cited by 301
Nordstrom, J. L., Gorlatov, S., Zhang, W., Yang, Y., Huang, L., Burke, S., Li, H., Ciccarone, V., Zhang, T., Stavenhagen, J., et al. (2011) · Breast Cancer Research · doi:10.1186/bcr3069 · Cited by 250
Reichert, J. M. (2017) · mAbs · doi:10.1080/19420862.2016.1269580 · Cited by 244
Self-citationKaplon, H., & Reichert, J. M. (2018) · mAbs · doi:10.1080/19420862.2018.1415671 · Cited by 244
Self-citationAntibody-based therapeutics to watch in 2011
Reichert, J. M. (2011) · mAbs · doi:10.4161/mabs.3.1.13895 · Cited by 236
Self-citationThe Mechanism of Action of the Anti-CD38 Monoclonal Antibody Isatuximab in Multiple Myeloma
Moreno, L., Perez, C., Zabaleta, A., Manrique, I., Alignani, D., Ajona, D., Blanco, L., Lasa, M., Maiso, P., Rodriguez, I., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-1597 · Cited by 221
Schnitzer, T. J., Easton, R., Pang, S., Levinson, D. J., Pixton, G., Viktrup, L., Davignon, I., Brown, M. T., West, C. R., & Verburg, K. M. (2019) · JAMA · doi:10.1001/jama.2019.8044 · Cited by 204 · cited 1×
“74 Patients were administered either 2.5 mg tanezumab at Day 1 and Week 8 (n = 231); 2.5 mg tanezumab at Day 1 and 5 mg at Week 8; or placebo at Day 1 and Week 8. From baseline to 16 weeks, mean WOMAC Pain scores decreased from 7.1 to 3.6 in the tanezumab 2.5 mg group; 7.3 to 3.6 in the tanezumab 2.5/5 mg group; and 7…”
MethodInfluentialReichert, J. M. (2016) · mAbs · doi:10.1080/19420862.2015.1125583 · Cited by 175
Self-citationPascal, K. E., Dudgeon, D., Trefry, J. C., Anantpadma, M., Sakurai, Y., Murin, C. D., Turner, H. L., Fairhurst, J., Torres, M., Rafique, A., et al. (2018) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiy285 · Cited by 175
Goldenberg, D. M., & Sharkey, R. M. (2019) · mAbs · doi:10.1080/19420862.2019.1632115 · Cited by 164
Reichert, J. M. (2014) · mAbs · doi:10.4161/19420862.2015.988944 · Cited by 156
Self-citationKutlar, A., Kanter, J., Liles, D., Alvarez, O. A., Cançado, R. D., Friedrisch, J. R., Knight‐Madden, J., Bruederle, A., Shi, M. M., Zhu, Z., et al. (2018) · American Journal of Hematology · doi:10.1002/ajh.25308 · Cited by 129
Which are the antibodies to watch in 2013?
Reichert, J. M. (2013) · mAbs · doi:10.4161/mabs.22976 · Cited by 128
Self-citationReichert, J. M. (2010) · mAbs · doi:10.4161/mabs.2.1.10677 · Cited by 106
Self-citationReichert, J. M. (2013) · mAbs · doi:10.4161/mabs.27333 · Cited by 96
Self-citationRugo, H. S., Im, S.-A., Wright, G. L. S., Escriva-de-Romani, S., DeLaurentiis, M., Cortes, J., Bahadur, S. W., Haley, B. B., Oyola, R. H., Riseberg, D. A., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.1000 · Cited by 80
Antibodies to watch in 2014: Mid-year update
Reichert, J. M. (2014) · mAbs · doi:10.4161/mabs.29282 · Cited by 53
Self-citationKellner, C., Zhukovsky, E. A., Pötzke, A., Brüggemann, M., Schrauder, A., Schrappe, M., Kneba, M., Repp, R., Humpe, A., Gramatzki, M., et al. (2013) · Leukemia · doi:10.1038/leu.2012.373 · Cited by 43
Cellular Mechanisms of Etrolizumab Treatment in Inflammatory Bowel Disease
Lichnog, C., Klabunde, S., Becker, E., Fuh, F. K., Tripal, P., Atreya, R. N., Klenske, E., Erickson, R., Chiu, H. H., Reed, C., et al. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00039 · Cited by 40
Long, G. V., Lebbé, C., Atkinson, V. G., Mandalà, M., Nathan, P., Fernandez, A. M. A., Richtig, E., Yamazaki, N., Robert, C., Schadendorf, D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.2019.37.15_suppl.9531 · Cited by 36
Kostareva, O. S., Kolyadenko, I., Ulitin, A. B., Ekimova, V., Evdokimov, S., Garber, M., Tishchenko, S., & Gabdulkhakov, A. G. (2019) · Crystals · doi:10.3390/cryst9030177 · Cited by 8
CRYSTAL STRUCTURE OF vhh-based FAB-fragment of antibody BCD-085
Kostareva, O. S., Kolyadenko, I., Ulitin, A. B., Ekimova, V. M., Evdokimov, S., Garber, M., Tishchenko, T. V., & Gabdulkhakov, A. G. (2019) · Worldwide Protein Data Bank · doi:10.2210/pdb6qkd/pdb · Cited by 4
Cited by
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q.-Y., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 484
A Decade of FDA-Approved Drugs (2010–2019): Trends and Future Directions
Brown, D. G., & Wobst, H. J. (2021) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c01516 · Cited by 320
Protein Design: From the Aspect of Water Solubility and Stability
Qing, R., Hao, S., Smorodina, E., Jin, D., Zalevsky, A., & Zhang, S. (2022) · Chemical Reviews · doi:10.1021/acs.chemrev.1c00757 · Cited by 312
Kaplon, H., & Reichert, J. M. (2021) · mAbs · doi:10.1080/19420862.2020.1860476 · Cited by 292
Self-citationPhage Display Derived Monoclonal Antibodies: From Bench to Bedside
Alfaleh, M. A., Alsaab, H. O., Mahmoud, A. B., Alkayyal, A. A., Jones, M. L., Mahler, S. M., & Hashem, A. M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01986 · Cited by 273
Metadata
- Authors
- Kaplon, H., Muralidharan, M., Schneider, Z., & Reichert, J. M.
- Venue
- mAbs
- Publisher
- Informa UK Limited
- Published
- 2019-12-26
- Volume
- 12
- Issue
- 1
- Pages
- 1703531-1703531
- ISSN
- 1942-0862 (ISSN-L)
- 1942-0870
- OpenAlex
- W2995764973
- Cited by
- 429
- References
- 32
- FWCI
- 49.64
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.